ClinicalTrials.gg
Not yet recruitingNCT05595187Updated Dec 14, 2023

Concomitant Tricuspid Repair in Patients With Left Heart Surgery

An interventional study of Tricuspid repair in Tricuspid Regurgitation, Mitral Regurgitation and Cardiopulmonary Bypass, sponsored by Nanjing Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Tricuspid Valve Insufficiency with a site in China — 19 open to participants now, 21 under way, none of them phase 3. Tricuspid Valve Insufficiency · China.

Planned enrollment
Largest of 16
400 · median 129
Started
2024
with 5 others
No phase
15 of 28
9 open now
Primary completion
2026-12
later than 7 of 20 live
Registered
11th of 28
by date
Lead sponsor
2 of 28
Nanjing Medical University

Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, this one has the largest planned enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2024, is one of 15 with no phase, reaches primary completion later than 7 of the 20 other live ones, and was the 11th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

19 of the 28 studies in Tricuspid Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Tricuspid Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

Tricuspid regurgitation is common in patients with severe left heart diseases, such as degenerative mitral regurgitation. However, the evidence base is insufficient to inform a decision about whether to perform concomitant tricuspid-valve repair during left heart surgery in patients who have mild tricuspid regurgitation. To inform decision making, we will conduct a multicenter, randomized trial to assess the benefits and risks of tricuspid-valve repair at the time of left heart diseases in patients with mild tricuspid regurgitation who were undergoing surgery for left heart surgery.

03

Conditions studied

  • Tricuspid Regurgitation
  • Mitral Regurgitation
  • Cardiopulmonary Bypass
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients undergoing left heart valve surgery with mild tricuspid regurgitation;
  2. Patients aged 18-80 years;
  3. Agree to participate in this study and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Infective endocarditis within 3 months;
  2. Primary tricuspid regurgitation;
  3. Isolated tricuspid regurgitation
  4. Lactating women and suspected pregnant or pregnant women;
  5. Patients with mental disorders, drug and alcohol dependence;
  6. Those who participated in other clinical trials one month before the trial;
  7. Refusal to participate in this study without .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Tricuspid repair

    Tricuspid repair techniques included suture placement and the type of prosthetic annuloplasty with specified the use of an approved rigid, incomplete, nonplanar, and undersized (ranging 26, 28, or 30, 32, 34 mm) ring.

    Device: Tricuspid repair

  • No intervention
    Blank control

Interventions

  • DeviceTricuspid repair

    Tricuspid repair included suture placement and the type of prosthetic annuloplasty.

06

What researchers measure

Primary outcomes

  1. A composite of adverse cardiovascular events

    a composite of reoperation for tricuspid regurgitation, progression of tricuspid regurgitation from baseline by two grades or the presence of severe tricuspid regurgitation, or death.

    Time frame: 2 years after surgery at follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for Dec 2026, 31 months later.

Of 86 interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2022
First posted
Oct 26, 2022
StartEst.
May 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05595187
Responsible party
Hong Liu (Principal Investigator of Cardiovascular Surgery, Nanjing Medical University) — Principal investigator
First posted
Oct 26, 2022
Start date
May 1, 2024 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 14, 2023

Study contacts

Hong Liu, MD
Contact
dr.hongliu@foxmail.com
18801281613
Yong-feng Shao, MD
Contact
yfshaojph@sina.com
02568303101

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion